Survival Outcomes of Uterine Malignancies in Chinese Population

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03291275

Enrollment

10000

Registered

2017-09-25

Start date

2017-09-01

Completion date

2023-09-01

Last updated

2018-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial Neoplasms, Survival

Brief summary

This study aims to determine survival outcomes (overall survival and progression-free survival) of primary uterine malignancies in China and relevant risk factors in a prospective cohort study.

Interventions

OTHERFollow-up for death and recurrence

All patients are followed up to determine definite date of diagnosis, recurrence and death.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Inclusion criteria

* Primary uterine malignancies.

Exclusion criteria

* Metastatic malignancies to uterine corpus

Design outcomes

Primary

Measure	Time frame	Description
Overall survival	5 years	Survival duration from diagnosis to death
Progression-free survival	5 years	Survival duration from last treatment after remission to recurrence

Countries

China

Contacts

Primary ContactLei Li, MD

lileigh@163.com13911988831

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026